Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,529.50
Bid: 1,531.50
Ask: 1,532.00
Change: 3.50 (0.23%)
Spread: 0.50 (0.033%)
Open: 1,537.00
High: 1,541.50
Low: 1,523.00
Prev. Close: 1,526.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London midday: Stocks bounce back after recent sell-off

Tue, 28th May 2013 11:20

UK markets were registering impressive gains on Tuesday morning with hopes of continued monetary easing in the Eurozone lifting sentiment as stocks bounced back following last week's sharp sell-off.After reaching a 13-year high on Wednesday, the FTSE 100 dropped sharply in the latter part of last week - losing nearly 3.0% in just two days - on fears of a scaling back of stimulus measures from the US Federal Reserve as well as some gloomy economic data from China.However with UK and US markets closed for national holidays on Monday, traders were looking to play catch up after missing out on the previous day's rally. Helping the bullish mood today were comments from European Central Bank (ECB) board member Peter Praet who said that the bank could still cut interest rates if needed to support the economy. In recent interviews, Praet said that "even after cutting the cost of money to a record low of 0.50%, the ECB signalled that the possibility of further easing was not exhausted".Market Analyst Craig Erlam from Alpari said: "Investor sentiment is on the rise in Europe this morning, with stock indices following in the footsteps of their Asian counterparts over night, which recovered early losses to end the session higher." Tuesday's session was the first positive day on Tokyo's Nikkei index since it dropped by 7.3% on Thursday."Now that the dust is beginning to settle, we could be seeing traders take advantage of the dip in the market to buy on the cheap. Given that the Bank of Japan's massive bond buying programme is only just getting under way, I think this will be the case," Erlam said.The economic data calendar was on the light side on Tuesday morning in Europe, though eyes will be fixed on consumer confidence and home-price figures in the States due out this afternoon.FTSE 100: TUI Travel, pharmas and banks provide a liftTour operator TUI Travel was among the best performers this morning, rising in sympathy with French peer Club Mediterranee after its shareholders Fosun International and Axa Private Equity joined forces to make a €540m bid for the firm.Drugs giant AstraZeneca higher after saying that it will continue to "vigorously" defend the intellectual property rights protecting its asthma medicine Pulmicort Respules. The company is appealing against a US court ruling that the patent protecting Pulmicort from rival drugs in the US is invalid. Sector peers Shire and GlaxoSmithKline were also in demand early on, with the latter being boosted by an upgrade by Deutsche Bank to 'buy'.Financial stocks were also performing well as markets on the whole rebounded from last week's sell-off. HSBC, Barclays and Standard Chartered were in positive territory, joined by part-nationalised lenders RBS and Lloyds which were both shrugging off downgrades by Citigroup today.Wood Group was also higher on news that its PSN business will continue to provide duty holder and asset management services to the Hummingbird Spirit floating storage offloading production vessel, under a new contract extension worth $87m from Teekay. Positive comments from Bank of America Merrill Lynch were helping share prices of a number of retailers this morning after the broker raised its target prices for Sainsbury, Marks & Spencer and Tesco.FTSE 250: Victrex jumps after first-half reportPolymer manufacturer Victrex was a high riser on the second-tier index after increasing its interim dividend by 15% despite a slight fall in profits. The company however still managed to beat profit before tax forecasts by 2.0% in the first half.Soft drinks maker AG Barr was also up as it managed to increase revenues by 2.4% in the first quarter in spite of the dismal weather.Mining firm Kazakhmys was heading the other way after announcing that it has sold its long-held German copper products unit MKM for €42m. "MKM is an excellent business, but did not fit with our geographic and strategic focus as a natural resources company in Central Asia," the company said.FTSE 100 - RisersPetrofac Ltd. (PFC) 1,391.00p +3.81%Barclays (BARC) 328.95p +3.77%TUI Travel (TT.) 371.50p +3.63%CRH (CRH) 1,438.00p +3.45%Weir Group (WEIR) 2,373.00p +3.40%Melrose Industries (MRO) 263.70p +3.33%GKN (GKN) 305.90p +3.21%International Consolidated Airlines Group SA (CDI) (IAG) 281.60p +3.15%Babcock International Group (BAB) 1,202.00p +3.09%AstraZeneca (AZN) 3,534.00p +3.09%FTSE 100 - FallersEurasian Natural Resources Corp. (ENRC) 249.00p -2.28%Randgold Resources Ltd. (RRS) 4,921.00p -1.34%Severn Trent (SVT) 2,049.00p -1.06%Anglo American (AAL) 1,549.00p -0.48%United Utilities Group (UU.) 784.00p -0.38%Carnival (CCL) 2,229.00p -0.36%Glencore Xstrata (GLEN) 331.75p -0.03%Rio Tinto (RIO) 2,866.50p -0.02%FTSE 250 - RisersNew World Resources A Shares (NWR) 115.20p +8.88%Victrex (VCT) 1,720.00p +5.65%Pace (PIC) 260.00p +4.00%Ferrexpo (FXPO) 177.20p +3.99%Telecity Group (TCY) 979.50p +3.93%Laird (LRD) 212.10p +3.87%Inchcape (INCH) 569.50p +3.73%Ashtead Group (AHT) 655.00p +3.39%Spirax-Sarco Engineering (SPX) 2,881.00p +3.37%Homeserve (HSV) 263.60p +3.37%FTSE 250 - FallersHochschild Mining (HOC) 241.30p -2.43%Kazakhmys (KAZ) 318.40p -2.36%AZ Electronic Materials SA (DI) (AZEM) 316.30p -2.23%Kenmare Resources (KMR) 31.00p -2.08%Dunelm Group (DNLM) 854.00p -1.84%EnQuest (ENQ) 131.50p -1.28%Telecom Plus (TEP) 1,271.00p -1.24%Salamander Energy (SMDR) 164.80p -1.20%HICL Infrastructure Company Ltd (HICL) 128.60p -1.08%Carpetright (CPR) 635.00p -1.01%
More News
16 Jun 2023 17:01

LONDON MARKET CLOSE: FTSE 100 ends a week of rate decisions higher

(Alliance News) - Stocks in London ended largely higher on Friday, following a busy week centred on the interest rate decisions of three major central banks.

Read more
16 Jun 2023 11:59

GSK cancer drug delay by FDA not "necessarily a red flag"

(Alliance News) - GSK PLC must gain approval for its "centrepiece" cancer drug momelotinib to validate its mergers & acquisitions pipeline but the extension of its review period in the US does not automatically spell trouble, according to analysis from Shore Capital on Friday.

Read more
16 Jun 2023 07:47

FDA extends review period of GSK blood cancer drug momelotinib

(Sharecast News) - GSK said on Friday that the US Food and Drug Administration has extended the review period of its new drug application for momelotinib, which is used to treat a blood cancer called myelofibrosis.

Read more
16 Jun 2023 07:42

IN BRIEF: GSK says FDA extending review period for blood cancer drug

GSK PLC - Brentford, England-based pharmaceutical company - Says US Food & Drug Administration has extended the review period of the new drug application for momelotinib by three months. Extension aims to provide time to review recently submitted data. The extended action date is September 16. Momelotinib uses "novel mechanism of action" to treat myelofibrosis, a rare blood cancer, as well as progressive anaemia which characterises the disease. Myelofibrosis affects approximately 25,000 US patients. The drug is not currently approved in any markets. GSK says it is "confident in the momelotinib NDA and looks forward to working with the FDA as they finalise their review."

Read more
9 Jun 2023 06:53

AstraZeneca hails RSV drug nirsevimab recommendation by FDA committee

(Alliance News) - AstraZeneca PLC on Thursday said that a US Food & Drug Administration committee unanimously recommended its antibody nirsevimab.

Read more
8 Jun 2023 12:09

London "still attractive" place to list, as IPO activity trickles back

(Alliance News) - A recent revival of initial public offerings in London's equity markets is encouraging evidence that the city still holds appeal on the global stage, analysts contended.

Read more
7 Jun 2023 09:22

EU approves its first vaccine for common respiratory virus RSV

June 7 (Reuters) - European regulators have approved the region's first vaccine for respiratory syncytial virus (RSV), which causes thousands of hospitalisations and deaths annually.

Read more
7 Jun 2023 09:10

LONDON MARKET OPEN: Stocks head lower amid global growth fears

(Alliance News) - Stock prices in London opened in the red on Wednesday, as concerns about interest rate hikes and a global economic slowdown damped risk appetite.

Read more
7 Jun 2023 07:59

TOP NEWS: GSK's Arexvy is first EU-approved RSV jab for older adults

(Alliance News) - GSK PLC on Wednesday announced that its RSV vaccine Arexvy has become the first EU-backed vaccine against the respiratory syncytial virus for adults aged 60 and older.

Read more
7 Jun 2023 07:34

GSK gets European approval for RSV vaccine

(Sharecast News) - Pharmaceuticals giant GSK announced on Wednesday that the European Commission has granted authorisation for 'Arexvy' - an adjuvant respiratory syncytial virus (RSV) vaccine - for active immunisation to prevent RSV-caused lower respiratory tract disease (LRTD) in adults 60 and older.

Read more
6 Jun 2023 08:34

US FDA accepts GSK's licence application for cancer treatment Jemperli

(Alliance News) - GSK PLC on Tuesday said the US Food & Drug Administration accepted its supplemental biologics licence application for endometrial cancer treatment dostarlimab, or Jemperli, after it was granted priority review in September.

Read more
6 Jun 2023 07:41

PRESS: Unilever starts search to replace Nils Andersen as chair

(Alliance News) - Unilever PLC has appointed executive search firm Spencer Stuart to find a replacement for Chair Nils Andersen, Bloomberg reported on Monday, citing "people familiar with the situation".

Read more
6 Jun 2023 07:18

US FDA accepts GSK supplemental application for Jemperli cancer drug

(Sharecast News) - GSK said the US Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application for its Jemperli treatment of adults with primary advanced or recurrent endometrial cancer.

Read more
2 Jun 2023 21:42

IN THE KNOW: hVIVO involvement in drug approval should boost interest

(Alliance News) - hVIVO's involvement in the approval of pharmaceutical giant Pfizer's new vaccine Abrysvo should support interest in its services, according to Liberum.

Read more
31 May 2023 23:35

US FDA approves Pfizer's RSV vaccine

May 31 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved Pfizer Inc's respiratory syncytial virus (RSV) vaccine for older adults, making it the second shot against the common respiratory disease that can be fatal for seniors.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.